News: Abraxis BioScience Acquires Shimoda Biotech and Platco …
November 20th, 2008Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated
biotechnology company, today announced the completion of the
acquisition of Shimoda Biotech (Pty) Ltd and its subsidiary, Platco
Technologies (Pty) Ltd, located in Plettenberg Bay, South Africa.
Shimoda Biotech focuses on the development of new pharmaceutical
products by combining successful off-patent molecules with a novel
cyclodextrin drug delivery platform, seeking …
Bandolier - Topical diclofenac 3% plus sodium hyaluronate for actinic keratosis
November 16th, 2008Actinic keratosis (AK), also referred to as solar keratosis or squamous cell carcinoma in situ (SCC), is a localised area of dysplasia with malignant potential. It is regarded as a strong predictor of a subsequent squamous cell carcinoma, a form of non-melanoma skin cancer. The risk of progression of AK to invasive SCC has been estimated to range from
Related Results
…
Journal of Orthopaedic Surgery - Nicolau syndrome following intramuscular diclofenac administration: a case report
November 10th, 2008ABSTRACT
Nicolau syndrome (livedoid dermatitis) is a rare adverse reaction of a still largely unidentified pathogenesis at the site of intramuscular drug injection. The typical presentation is pain around the injection site soon after injection, followed by erythema, li…
Journal of Drugs in Dermatology - Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face…
November 7th, 2008 Abstract
Actinic keratoses (AKs) are a common precancerous condition and are said to account for 14% of visits to dermatologists in the US each year. Along with cryotherapy, topical treatments are a mainstay of therapy for these lesions. One of the potential benefits of topical…
Business Wire - Swiss Drug Delivery Firm Licenses Fast-Acting Diclofenac Products to U.S. Based ProEthic Pharmaceuticals
November 5th, 2008MONTGOMERY, Ala. & BALERNA, Switzerland — Applied Pharma Research (APR), a Swiss-based R&D firm that specializes in enhancing drug delivery, and ProEthic Pharmaceuticals Inc., announced today that APR has granted an exclus…
Medical Marketing and Media - Endo, Novartis begin agreement
November 1st, 2008ENDO Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for Voltaren Gel (diclofenac sodium topical gel) 1%. Endo said it expects to commercialize Voltaren Gel using one of its two specialty sales forc…
Journal of Family Practice - Diclofenac more effective than acetaminophen in osteoarthritis of the knee
October 26th, 2008 Case JP, Baliumnas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis. A randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003; 163:169-178.
* PRACTICE RECOMMENDATIONS
Diclofenac 150…
Phytomedicine: International Journal of Phytotherapy & Phytopharmacology - Efficacy of a Comfrey root extract ointment in comparison to a Diclofenac gel in the treatment of ankle distortions: results of an observer-blind, randomized,…
October 23rd, 2008Abstract
Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
How To Get A Job Offer From Every Interview
…
PR Newswire Europe - Australian Government TGA Approves Registration of Solaraze(R) 3% Gel (diclofenac sodium) for the Management of Actinic Keratosis.
October 18th, 2008BASINGSTOKE, England, November 28 /PRNewswire/ — Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that the Australian Government Department of Health and Ageing Therapeutic Goods Administration (TGA) has approved the registration of Solaraze(R) 3% Gel (diclofenac sodium) for the management of actinic keratosis (AK). Actinic keratosis is the most …
Journal of Drugs in Dermatology - Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel
October 17th, 2008 Abstract
A clearance rate of all occurrences [greater than or equal to]75% for actinic keratoses (AK) lesions is an accepted efficacy endpoint for topical agents. This efficacy endpoint has not been assessed for 3.0% diclofenac sodium gel (Solaraze[TM]).
We evaluated the effic…


